UCB | UCB Annual Report & Investor Relations Data
ISIN
BE0003739530
Ticker
UCB
Sector
Industry
Country
Belgium
Year Founded
1928
ISIN
BE0003739530
Ticker
UCB
Sector
Industry
Country
Belgium
Year Founded
1928
A global biopharma company, inspired by the needs of people living with severe diseases.
At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong.
Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.
UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.
8,600
Worldwide
| Type | Document | Details | Language | Filing Date | File Number |
|---|
Access comprehensive European stock market filings data through a single, powerful API.
1,5M+
filings covered
18
European countries
30min
max latency
1 API
for all filings
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 14.10.2024 | Caeymaex Emmanuel | Executive member | Sell | EUR 231,518.11 |
| 14.10.2024 | Caeymaex Emmanuel | Executive member | Sell | EUR 188,760.81 |
| 04.10.2024 | Fleurial Jean-Luc | Executive member | Sell | EUR 1,443,526.51 |
| 04.10.2024 | Fleurial Jean-Luc | Executive member | Buy | EUR 662,645.95 |
| 04.10.2024 | Johnson Waynick Denelle | Executive member | Buy | EUR 6,192.45 |
| 12.09.2024 | Caeymaex Emmanuel | Executive member | Sell | EUR 653,400.00 |
| 12.09.2024 | Caeymaex Emmanuel | Executive member | Buy | EUR 281,040.00 |
| 05.09.2024 | Caeymaex Emmanuel | Executive member | Sell | EUR 646,200.00 |
| 05.09.2024 | Caeymaex Emmanuel | Executive member | Buy | EUR 281,040.00 |
| 01.08.2024 | Caeymaex Emmanuel | Executive member | Sell | EUR 669,075.70 |
We currently don't have information about the management or supervisory board for this company. This information will be updated as soon as it becomes available.
BE0003739530
2138008J191VLSGY5A09
BEL20
ABVX
Sector
Health Care
Country
France
ISIN
FR0012333284
Founded
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections …
ADXN
Sector
Health Care
Country
Switzerland
ISIN
CH0029850754
Founded
2002
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally …
AEGIR
Sector
Health Care
Country
Sweden
ISIN
SE0014401121
Founded
2019
AegirBio is a Swedish diagnostics company that was founded to offer tests to monitor and optimize the dosage of biological …
None
Sector
Health Care
Country
North Macedonia
ISIN
MKALKA101011
Founded
1936
Alkaloid AD Skopje is a company which more than eight and a half decades, has been operating in the field …
ATB
Sector
Health Care
Country
Romania
ISIN
ROATBIACNOR9
Founded
1955
The leading manufacturer of generic drugs in Romania, Antibiotice SA was founded in December 1955. The company was listed on …
AZN
Sector
Health Care
Country
United Kingdom
ISIN
GB0009895292
Founded
1999
We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science …